{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:16:31Z","timestamp":1789391791658,"version":"build-2803163510"},"reference-count":150,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1053\/j.gastro.2021.04.023","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T04:08:56Z","timestamp":1622002136000},"page":"2512-2556.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease"],"prefix":"10.1053","volume":"160","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngve","family":"Falck-Ytter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Feuerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.04.023_bib1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.023_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult crohn's disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib4","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.cgh.2018.12.022","article-title":"Decreasing risk of first and subsequent surgeries in patients with Crohn's disease in England from 1994 through 2013","volume":"17","author":"Burr","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","article-title":"Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study","volume":"68","author":"Burisch","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib6","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: A Meta-analysis of population-based cohorts","author":"Tsai","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cgh.2019.11.034","article-title":"Identifying patients with inflammatory bowel diseases at high vs low risk of complications","volume":"18","author":"Siegel","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.cgh.2014.11.020","article-title":"Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States","volume":"13","author":"Ananthakrishnan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib9","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1097\/MIB.0000000000000933","article-title":"Variation in care of inflammatory bowel diseases patients in Crohn's and Colitis Foundation of America partners: role of gastroenterologist practice setting in disease outcomes and quality process measures","volume":"22","author":"Weaver","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.023_bib10","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases","volume":"153","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib12","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"Casellas","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2021.04.023_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/apt.13973","article-title":"Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease","volume":"45","author":"Jairath","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.gastro.2021.04.023_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.04.023_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1053\/j.gastro.2021.04.023_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib20","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.04.023_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2021.04.023_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2021.04.023_bib23","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.04.023_bib24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","article-title":"Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases","volume":"17","author":"Beaugerie","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib27","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Lymphoma risk and overall safety profile of adalimumab in patients with Crohn's Disease with up to 6 years of follow-up in the Pyramid Registry","volume":"113","author":"D'Haens","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib30","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2021.04.023_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-alpha-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib34","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Danese S, et\u00a0al. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies [published online ahead of print September 23, 2020]. Inflamm Bowel Dis https:\/\/doi.org\/10.1093\/ibd\/izaa236","DOI":"10.1093\/ibd\/izaa236"},{"key":"10.1053\/j.gastro.2021.04.023_bib35","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.04.023_bib38","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.04.023_bib39","doi-asserted-by":"crossref","unstructured":"Muller M, D'Amico F, Bonovas S, et\u00a0al. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review [published online ahead of print September 11, 2020]. J Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa186.","DOI":"10.1093\/ecco-jcc\/jjaa186"},{"key":"10.1053\/j.gastro.2021.04.023_bib40","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.04.023_bib41","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib42","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib44","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib46","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib47","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.023_bib48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.023_bib51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"issue":"2007","key":"10.1053\/j.gastro.2021.04.023_bib54","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib57","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib58","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A\u00a0randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib61","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib62","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib63","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib64","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib65","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib66","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1053\/j.gastro.2021.04.023_bib67","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib68","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2018001","article-title":"Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica","volume":"40","author":"Paz","year":"2018","journal-title":"Epidemiol Health"},{"key":"10.1053\/j.gastro.2021.04.023_bib69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ibd.21007","article-title":"Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies","volume":"16","author":"Duricova","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.023_bib70","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/apt.14466","article-title":"Comparison of infliximab with adalimumab in 827 biologic-naive patients with Crohn's disease: a population-based Danish cohort study","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib71","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cgh.2016.03.038","article-title":"Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn's disease","volume":"14","author":"Singh","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib72","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.023_bib73","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/apt.15706","article-title":"The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor","volume":"51","author":"Alric","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib74","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/apt.16057","article-title":"Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease","volume":"52","author":"Townsend","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.15745","article-title":"Ustekinumab is associated with superior effectiveness outcomes compared with vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment","volume":"52","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib76","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1053\/j.gastro.2021.04.023_bib77","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib78","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease","volume":"145","author":"Pan\u00e9s","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib79","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib80","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib81","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A\u00a0comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease","volume":"342","author":"Feagan","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib82","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ajg.2013.402","article-title":"The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis","volume":"109","author":"Chatu","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib84","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib85","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.gastro.2014.09.031","article-title":"Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis","volume":"148","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib87","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib88","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjaa050","article-title":"Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications","volume":"14","author":"Targownik","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.023_bib89","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.cgh.2018.11.003","article-title":"Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study","volume":"17","author":"Targownik","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib90","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.023_bib91","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cgh.2020.06.071","article-title":"No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis","volume":"19","author":"Yzet","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib92","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","volume":"11","author":"Vermeire","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib93","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib94","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib95","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib96","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00535-019-01582-w","article-title":"Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)","volume":"54","author":"Hisamatsu","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib98","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2017.09.061","article-title":"Outcomes 7 years after infliximab withdrawal for patients with Crohn's disease in sustained remission","volume":"16","author":"Reenaers","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib99","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib100","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic Review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"issue":"2008","key":"10.1053\/j.gastro.2021.04.023_bib101","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.023_bib102","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ecco-jcc\/jjy014","article-title":"Long-term outcome of early combined immunosuppression versus conventional management in newly diagnosed Crohn's disease","volume":"12","author":"Hoekman","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.04.023_bib103","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.023_bib104","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib105","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1053\/j.gastro.2021.04.023_bib107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib108","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group","volume":"12","author":"Ferguson","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib109","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib111","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib112","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National cooperative Crohn's disease study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib113","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gut.19.7.606","article-title":"Low dose steroids and clinical relapse in Crohn's disease: a controlled trial","volume":"19","author":"Smith","year":"1978","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib114","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib116","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib117","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A\u00a0comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib118","first-page":"PI29","article-title":"Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study","volume":"12","author":"Tursi","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1053\/j.gastro.2021.04.023_bib119","first-page":"CD003715","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease","volume":"9","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2021.04.023_bib120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib121","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2021.04.023_bib122","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ibd\/izaa127","article-title":"Trends of 5-aminosalicylate medication use in patients with Crohn disease","volume":"27","author":"Noureldin","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.023_bib123","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib124","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib125","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn's disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2036.2010.04509.x","article-title":"Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease\u2014subgroup results from a placebo-controlled study","volume":"33","author":"Schreiber","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib127","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising Crohn's disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2021.04.023_bib128","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.1093\/ecco-jcc\/jjz203.605","article-title":"P476 Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulising Crohn\u2019s disease: results of the ENTERPRISE study","volume":"14","author":"Schwartz","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2021.04.023_bib129","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S0016-5085(17)30930-7","article-title":"Fistula healing in pivotal studies of ustekinumab in Crohn's disease","volume":"152","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.04.023_bib131","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ibd.20608","article-title":"Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study","volume":"15","author":"Thia","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.023_bib132","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","article-title":"Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study","volume":"20","author":"West","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib133","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","article-title":"Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)","volume":"63","author":"Dewint","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.04.023_bib134","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cgh.2019.05.010","article-title":"Variation among patients with Crohn's disease in benefit vs risk preferences and remission time equivalents","volume":"18","author":"Bewtra","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227635","article-title":"Patient preferences for maintenance therapy in Crohn's disease: a discrete-choice experiment","volume":"15","author":"Hazlewood","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.04.023_bib136","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2015.321","article-title":"Inflammatory bowel disease patients' willingness to accept medication risk to avoid future disease relapse","volume":"110","author":"Bewtra","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185500","article-title":"A\u00a0systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease","volume":"12","author":"Pillai","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.04.023_bib138","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.gastro.2020.08.064","article-title":"Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases","volume":"160","author":"Barnes","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.04.023_bib139","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/ajg.2010.202","article-title":"Racial disparities in utilization of specialist care and medications in inflammatory bowel disease","volume":"105","author":"Nguyen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib140","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2013.192","article-title":"The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States","volume":"108","author":"Lin","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.04.023_bib141","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1007\/s10620-010-1442-8","article-title":"Race and inflammatory bowel disease in an urban healthcare system","volume":"55","author":"Sewell","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2021.04.023_bib142","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ibd.20825","article-title":"Hospitalizations for inflammatory bowel disease: profile of the uninsured in the United States","volume":"15","author":"Nguyen","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.04.023_bib143","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.cgh.2020.01.023","article-title":"Assessing national trends and disparities in ambulatory, emergency department, and inpatient visits for inflammatory bowel disease in the United States (2005-2016)","volume":"18","author":"Ma","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.04.023_bib144","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.gastro.2020.08.060","article-title":"AGA Clinical Practice update on management of inflammatory bowel disease in elderly patients: expert review","volume":"160","author":"Ananthakrishnan","year":"2021","journal-title":"Gastroenterology"},{"issue":"10114","key":"10.1053\/j.gastro.2021.04.023_bib145","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.023_bib146","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.023_bib147","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2021.04.023_bib148","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2036.2009.04037.x","article-title":"Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections","volume":"30","author":"Schneeweiss","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.04.023_bib149","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.04.023_bib150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor \u03b1 inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2021.04.023_bib151","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521006466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521006466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:32:27Z","timestamp":1758036747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521006466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":150,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0016508521006466"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.04.023","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}